Refining antifibrotic therapy in idiopathic pulmonary fibrosis: can deuteration improve on pirfenidone?
American Journal of Respiratory and Critical Care Medicine · 01.08.2026 · 212 (8) · 1686-1687
DOI: 10.1093/ajrccm/aamag237 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory and Critical Care Medicine, online erschienen am 18.05.2026. Verfasst von Chad A Newton. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.
ORCID-Profile: Chad A Newton
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Newton, C. A. (2026). Refining antifibrotic therapy in idiopathic pulmonary fibrosis: can deuteration improve on pirfenidone?. American Journal of Respiratory and Critical Care Medicine, 212(8), 1686-1687. https://doi.org/10.1093/ajrccm/aamag237
Vancouver
Newton CA. Refining antifibrotic therapy in idiopathic pulmonary fibrosis: can deuteration improve on pirfenidone?. American Journal of Respiratory and Critical Care Medicine. 2026;212(8):1686-1687. doi:10.1093/ajrccm/aamag237
BibTeX
@article{Newton2026,
author = {Newton, Chad A},
title = {Refining antifibrotic therapy in idiopathic pulmonary fibrosis: can deuteration improve on pirfenidone?},
journal = {American Journal of Respiratory and Critical Care Medicine},
year = {2026},
volume = {212},
number = {8},
pages = {1686--1687},
doi = {10.1093/ajrccm/aamag237}
}
EUVIMED